555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [dự đoan xsmb]
Jun 14, 2025 · Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), survival …
May 28, 2025 · In the lurbinectedin and atezolizumab arm, 6.2% of patients stopped treatment due to side effects compared to 3.3% in the atezolizumab alone arm. “While the introduction of …
Aug 9, 2025 · Background The first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) has evolved from chemotherapy alone to chemoimmunotherapy. However, the …
Abstract Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, …
Oct 1, 2024 · IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech–sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of …
Sep 25, 2018 · The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and …
Jan 13, 2021 · Context Key Objective Based on results of the pivotal IMpower133 study, atezolizumab (anti–programmed death-ligand 1 [anti–PD-L1]) in combination with carboplatin …
May 22, 2025 · ALEXANDRIA, Va. — Results from a global phase 3 clinical trial found that maintenance therapy with a combination of lurbinectedin and atezolizumab helped some …
Abstract Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of …
Jun 10, 2025 · Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival …
Bài viết được đề xuất: